Partner David Rosen was quoted in a Newsweek article published on May 1, 2014, titled “Be Still, My Bioficial Heart.” The article explained the benefits and challenges of creating a “bioficial heart,” which researchers at the University of Louisville recently announced could be developed using living cells from a potential transplant patient combined with artificial materials to create a fully functional 3-D printed heart. Given that the U.S. Food and Drug Administration (FDA) is many years out from approving lab-built organs for patients, Rosen said, “The potential challenges include demonstrating that the organs will function as predicted, demonstrating the sustainability of these organs once transplanted and obtaining approval to test and market these from [the] FDA.”
People
Related News
June 20, 2025
In the News
Brian Wheeler and Lyman Thai Comment on Private Equity's Entry into Niche Sports
Foley & Lardner LLP partners Brian Wheeler and Lyman Thai described private equity's growing investments in niche sports in the Pensions & Investments article, "Ares Management buys minority stake in French sailing team."
June 16, 2025
In the News
Gregory Husisian on Customs Compliance Violations – 'It's a sharply increased risk profile'
Foley & Lardner LLP partner Gregory Husisian joined the SupplyChainBrain Thought Leaders episode, "Getting Ahead of Customs Compliance Violations," to describe the heightened risk environment importers face under the current trade and regulatory regime.
June 11, 2025
In the News
Foley Named Top US Firm for IP Lateral Hires by ManagingIP
Foley & Lardner LLP was named the top United States firm for intellectual property lateral partner hires in April and May 2025 based on data from ManagingIP's Talent Tracker.